Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation
sBLA expected to be filed in early 2022 Seven-day multidose vial and room temperature stability allow for the potential use of tesamorelin with a multidose pen injector MONTREAL, July 07, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies …